INCY (US45337C1027)
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs
Market: Nasdaq
Fair value: $ 84.00
Discount: N/A
Average yearly return: 26%
Yield: N/A
Marketperformer
In INCY ‘s most recent quarter, EPS moved to $0.12 from $0.29 in prior quarter and revenues reached at $263.46M versus $187.61M. Analysts had expected Incyte Corporation (NASDAQ:INCY) to report earnings of about $0.17 per share on $263.88M in revenue. Looking forward, analysts on average predict that earnings for the current quarter would come in between $-0.08 and $0.14. That is compared with the $0.05 in earnings per share it reported during the same period last year.
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs
Market: Nasdaq
Discount: N/A
Average yearly return: 26%
Yield: N/A
Marketperformer
In INCY ‘s most recent quarter, EPS moved to $0.12 from $0.29 in prior quarter and revenues reached at $263.46M versus $187.61M. Analysts had expected Incyte Corporation (NASDAQ:INCY) to report earnings of about $0.17 per share on $263.88M in revenue. Looking forward, analysts on average predict that earnings for the current quarter would come in between $-0.08 and $0.14. That is compared with the $0.05 in earnings per share it reported during the same period last year.
No comments:
Post a Comment